Dianthus Therapeutics, Inc. /DE/ Capital Expenditures
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Capital Expenditures of $245.00 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-03.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2023-08-03
- Dianthus Therapeutics, Inc. /DE/ payments to acquire property, plant, and equipment for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ payments to acquire property, plant, and equipment for the quarter ending 2023-03-31 was $245.00K, a 807.41% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ payments to acquire property, plant, and equipment for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ payments to acquire property, plant, and equipment for the quarter ending 2022-09-30 was $158.00K, a 86.03% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ payments to acquire property, plant, and equipment for fiscal 2022 was $314.00K, a 75.16% decline from fiscal 2021.
- Dianthus Therapeutics, Inc. /DE/ payments to acquire property, plant, and equipment for fiscal 2021 was $1.26M, a 216.00% increase from fiscal 2020.
- Dianthus Therapeutics, Inc. /DE/ payments to acquire property, plant, and equipment for fiscal 2020 was $400.00K, a 86.93% decline from fiscal 2019.
- Dianthus Therapeutics, Inc. /DE/ payments to acquire property, plant, and equipment for fiscal 2019 was $3.06M, a 60.11% decline from fiscal 2018.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $245.00K 10-Q · filed 2023-08-03 | $245.00K derived: sum of 3 quarters · filed 2023-08-03 | $403.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | $245.00K 10-Q · filed 2023-05-15 | $245.00K derived: sum of 2 quarters · filed 2023-05-15 | $403.00K derived: sum of 3 quarters · filed 2023-05-15 | $532.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $158.00K derived: sum of 2 quarters · filed 2023-03-23 | $287.00K derived: sum of 3 quarters · filed 2023-08-03 | $314.00K 10-K · filed 2023-03-23 |
| 2022-09-30 | $158.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $287.00K derived: sum of 2 quarters · filed 2023-08-03 | $314.00K 10-Q · filed 2022-11-03 | $329.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-06-30 | $129.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $156.00K 10-Q · filed 2023-08-03 | $171.00K derived: sum of 3 quarters · filed 2023-08-03 | $1.30M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $27.00K 10-Q · filed 2023-05-15 | $42.00K derived: sum of 2 quarters · filed 2023-05-15 | $1.17M derived: sum of 3 quarters · filed 2023-05-15 | $1.28M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $1.15M derived: sum of 2 quarters · filed 2023-03-23 | $1.26M derived: sum of 3 quarters · filed 2023-03-23 | $1.26M 10-K · filed 2023-03-23 |
| 2021-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.24M derived: sum of 2 quarters · filed 2022-11-03 | $1.25M 10-Q · filed 2022-11-03 | $1.46M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $111.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $118.00K 10-Q · filed 2022-08-04 | $331.00K derived: sum of 3 quarters · filed 2022-08-04 | $351.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $7.00K 10-Q · filed 2022-05-16 | $220.00K derived: sum of 2 quarters · filed 2022-05-16 | $240.00K derived: sum of 3 quarters · filed 2022-05-16 | $276.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $213.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $233.00K derived: sum of 2 quarters · filed 2022-03-08 | $269.00K derived: sum of 3 quarters · filed 2022-03-08 | $400.00K 10-K · filed 2022-03-08 |
| 2020-09-30 | $20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $56.00K derived: sum of 2 quarters · filed 2021-11-04 | $187.00K 10-Q · filed 2021-11-04 | $340.00K derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $167.00K 10-Q · filed 2021-08-05 | $320.00K derived: sum of 3 quarters · filed 2021-08-05 | $850.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $131.00K 10-Q · filed 2021-05-06 | $284.00K derived: sum of 2 quarters · filed 2021-05-06 | $814.00K derived: sum of 3 quarters · filed 2021-05-06 | $1.94M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $153.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $683.00K derived: sum of 2 quarters · filed 2021-03-03 | $1.81M derived: sum of 3 quarters · filed 2021-03-03 | $3.06M 10-K · filed 2021-03-03 |
| 2019-09-30 | $530.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.66M derived: sum of 2 quarters · filed 2020-11-05 | $2.91M 10-Q · filed 2020-11-05 | $7.26M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $2.38M 10-Q · filed 2020-08-06 | $6.73M derived: sum of 3 quarters · filed 2020-08-06 | $9.20M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $1.25M 10-Q · filed 2020-05-07 | $5.60M derived: sum of 2 quarters · filed 2020-05-07 | $8.08M derived: sum of 3 quarters · filed 2020-05-07 | $8.76M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $6.83M derived: sum of 2 quarters · filed 2020-03-03 | $7.51M derived: sum of 3 quarters · filed 2020-03-03 | $7.67M 10-K · filed 2020-03-03 |
| 2018-09-30 | $2.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $3.16M derived: sum of 2 quarters · filed 2019-11-13 | $3.32M 10-Q · filed 2019-11-13 | $3.64M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-06-30 | $685.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $846.00K 10-Q · filed 2019-08-08 | $1.16M derived: sum of 3 quarters · filed 2020-03-03 | $1.55M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-03-31 | $161.00K 10-Q · filed 2019-05-09 | $478.00K derived: sum of 2 quarters · filed 2020-03-03 | $863.00K derived: sum of 3 quarters · filed 2020-03-03 | |
| 2017-12-31 | $317.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $702.00K derived: sum of 2 quarters · filed 2020-03-03 | $2.20M 10-K · filed 2020-03-03 | |
| 2017-09-30 | $385.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.88M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $1.50M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $139.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |